-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1769 Characterization of the Platelet Phenotype Caused By a Germline RUNX1 Variant in a CRISPR/Cas9-Generated Murine Model

Program: Oral and Poster Abstracts
Session: 311. Disorders of Platelet Number or Function: Poster II
Hematology Disease Topics & Pathways:
Bleeding Disorders, Diseases, Bleeding and Clotting, Hemostasis, Genetic Disorders, Platelet Disorders, Thrombocytopenias
Sunday, December 6, 2020, 7:00 AM-3:30 PM

Ana Marín-Quílez, MSc1*, Ignacio García-Tuñón, PhD1*, Cristina Fernández-Infante, MSc1*, Hernández-Cano Luis, MSc1*, Veronica Palma-Barqueros, MSc2*, Sánchez-Martín Manuel, PhD1,3*, José Ramón González-Porras, MD, PhD4*, Guerrero Carmen, PhD1*, Rocio Benito, PhD1*, Jose Rivera, PhD2,5*, Jesus Maria Hernández-Rivas, MD, PhD1,4 and Jose Maria Bastida, MD, PhD4,6*

1IBSAL, IBMCC, CIC, Universidad de Salamanca-CSIC, Salamanca, Spain
2Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CB15/00055-CIBERER, Murcia, Spain
3Servicio de Transgénesis, Universidad de Salamanca, Salamanca, Spain
4Department of Hematology, University Hospital of Salamanca, IBSAL, Salamanca, Spain
5On behalf of the Project “Functional and Molecular Characterization of Patients with Inherited Platelet Disorders” of the Hemorrhagic Diathesis Working Group of the Spanish Society of Thrombosis and Haemostasis, Murcia, Spain
6On behalf of the Project “Functional and Molecular Characterization of Patients with Inherited Platelet Disorders” of the Hemorrhagic Diathesis Working Group of the Spanish Society of Thrombosis and Haemostasis, Salamanca, Spain

RUNX1-related disorder (RUNX1-RD) is caused by germline variants affecting RUNX1 gene. This rare and heterogeneous disorder has no specific clinical and laboratory phenotype, making genetic diagnosis necessary. Despite international recommendations have been established to classify the pathogenicity of variants, identifying the causative alteration remains a challenge in RUNX1-RD. Therefore, murine models may be useful not only to settle definitively the controversy about the pathogenicity of certain RUNX1 variants, but also to elucidate the mechanisms of molecular pathogenesis. Thus, we developed a knock-in murine model, using the CRISPR/Cas9 system, carrying the RUNX1 p.Leu43Ser variant (mimicking human p.Leu56Ser) to study its pathogenic potential and mechanisms of platelet dysfunction. A total number of 75 mice were generated; 25 per genotype (RUNX1WT/WT, RUNX1WT/L43S, RUNX1L43S/L43S). Platelet phenotype was assessed by flow cytometry and confocal microscopy. On average, RUNX1L43S/L43S and RUNX1WT/L43S mice had significantly prolonged bleeding-tail time than RUNX1WT/WT, indicating a role of the variant in hemostasis. Nevertheless, only homozygous mice displayed mild-thrombocytopenia. RUNX1L43S/L43S and RUNX1WT/L43S displayed impaired agonist-induced spreading and α-granule release, with no differences in δ-granule secretion. Levels of activation of integrin αIIbβ3, fibrinogen-binding, and aggregation were significantly lower in platelets from RUNX1L43S/L43S and RUNX1WT/L43S using PMA, ADP, and high-doses of thrombin. Lower levels of PKC phosphorylation in RUNX1L43S/L43S and RUNX1WT/L43S suggested that PKC-signaling pathway was impaired. Overall, we demonstrated the deleterious effect of the RUNX1 p.Leu56Ser variant in mice via the impairment of integrin αIIbβ3 activation, aggregation, α-granule secretion, and platelet spreading; mimicking the phenotype associated with RUNX1 variants in the clinical setting.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH